Get the Stockscreener App
128.66
2.56%
3.21
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $128.66, with a volume of 18.83M.
It is up +2.56% in the last 24 hours and up +7.47% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$125.45
Open:
$125.83
24h Volume:
18.83M
Relative Volume:
1.87
Market Cap:
$317.77B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
36.21
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
+12.99%
1M Performance:
+7.47%
6M Performance:
+20.49%
1Y Performance:
+63.21%
1-Day Range:
$125.83
$128.78
1-Week Range:
$113.00
$128.78
52-Week Range:
$76.66
$128.78
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
128.66 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,208.12 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
155.41 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Lost Money on Merck & Co., Inc. (MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - The National Law Review
Merck & Co. highlights oncology pipeline, shares supported by long-term drug portfolio - Ad-hoc-news.de
Merck & Co. Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Merck & Co., Inc. Actuals & Estimates (AQUISEU:6MKD) - TradingView
Merck & Co. sets Keytruda growth expectations, shares supported by oncology pipeline - Ad-hoc-news.de
Merck & Co., Inc. (MRK) is a trending stock: Facts to know before betting on it - MSN
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Qualcomm, Merck, Rockwell Automation: CNBC’s ‘Final Trades’Qualcomm (NASDAQ:QCOM), Simon Property Grou - Benzinga
Merck & Co. dividend track record, shares in focus on the NYSE - Ad-hoc-news.de
Cardano Risk Management B.V. Lowers Position in Merck & Co., Inc. $MRK - MarketBeat
Apella Capital LLC Has $4.42 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. lifts 2026 outlook, Keytruda and vaccines drive shares on Wall Street - Ad-hoc-news.de
Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh - TradingView
Enterprise value to revenue forward of Merck & Co., Inc. – HAN:6MK - TradingView
Merck & Co. updates pipeline and oncology focus, shares stay in the S&P 500 spotlight - Ad-hoc-news.de
Merck & Co., Inc. (NYSE:MRK) Sets New 12-Month HighTime to Buy? - MarketBeat
Merck & Co Inc Stock (MRK) Moved Up by 4.04% on Jun 25: A Full Analysis - TradingKey
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga
Merck & Co., Inc. Actuals & Estimates (NYSE:MRK) - TradingView
Price to sales forward of Merck & Co., Inc. – HAN:6MK - TradingView
Merck & Co. updates late-stage cancer pipeline, shares on NYSE radar - Ad-hoc-news.de
Merck (MRK) Stock Gets New Outperform Rating from CICC - Insider Monkey
Merck & Co., Inc. (NYSE:MRK) Now Covered by CICC Research - MarketBeat
Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsight - GlobeNewswire Inc.
Is Merck & Co., Inc. (MRK) Strengthening Its Vaccine Portfolio With New Capvaxive Approval? - Insider Monkey
Thrivent Large Cap Value Portfolio's Merck & Co Inc(MRK) Holding History - GuruFocus
CICC Initiates Merck & Co. at Outperform With $138 Price Target - marketscreener.com
THRIVENT HEALTHCARE PORTFOLIO's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co. clears a short-term technical mark, shares extend their recent advance - Ad-hoc-news.de
Is Merck & Co Inc (MRK) Overvalued After 3.6% Rally? GF Value Sa - GuruFocus
Merck & Co Inc Stock (MRK) Moved Up by 3.23% on Jun 23: Key Drivers Unveiled - TradingKey
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study - Yahoo Finance Singapore
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co. outlines strategic pipeline moves, shares hold steady on NYSE - AD HOC NEWS
Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy - Benzinga
Merck’s Oncology Engine Is Still Accelerating (NYSE:MRK) - Seeking Alpha
Merck & Co. eyes oncology and vaccine strategy, shares tracked against big pharma peers - AD HOC NEWS
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Business Wire
Berenberg Adjusts Price Target on Merck & Co. to $125 From $115, Maintains Hold Rating - marketscreener.com
Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise - Insider Monkey
Merck & Co. Stockweekly review and pharma peer comparison - AD HOC NEWS
Penn Series Large Core Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
LVIP MFS Value Fund's Merck & Co Inc(MRK) Holding History - GuruFocus
Is Merck's Recent Restructuring a Confident Pivot or a Defensive Maneuver - Kavout | AI
Merck & Co., Inc. Sued for Securities Law ViolationsInvestors - The National Law Review
Merck & Co. Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens - Benzinga
Merck granted U.S. label expansion for Capvaxive pneumococcal shot - Seeking Alpha
Merck's pneumococcal vaccine wins US approval for high-risk children, teens - Reuters
Here’s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now - Insider Monkey
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):